1.Research Progress of Regulatory T Cells in the Pathogenesis of Multiple Myeloma --Review.
Ya-Ting LIN ; Xue-Zhong GU ; Jun HE ; Xin GUAN ; Chao-Ran ZHANG
Journal of Experimental Hematology 2023;31(1):297-300
The multiple myeloma (MM), the second most common hematologic malignancy, is malignant proliferative disease of plasma cells. Although the application of many targeted drugs has significantly prolonged the survival time of MM patients, it is still an incurable disease. In recent years, the immunosuppression caused by interaction between tumor microenvironment(TME) and tumor cells has attracted people's attention gradually. As a kind of immunosuppressive cells in TME, regulatory T cells (Treg) play an important role in the progress of MM. Treg is related to the proliferation and metastasis of tumors, and can lead to the progress of MM by promoting the angiogenesis and generating immunosuppressive TME. In this review, we briefly summarized the latest research progress on the impact of Treg on the pathogenesis of MM.
Humans
;
Multiple Myeloma/pathology*
;
T-Lymphocytes, Regulatory/pathology*
;
Immune Tolerance
;
Plasma Cells/pathology*
;
Immunosuppression Therapy
;
Tumor Microenvironment
2.HIV-1 Subtype Diversity and Factors Affecting Drug Resistance among Patients with Virologic Failure in Antiretroviral Therapy in Hainan Province, China, 2014-2020.
De E YU ; Yu Jun XU ; Mu LI ; Yuan YANG ; Hua Yue LIANG ; Shan Mei ZHONG ; Cai QIN ; Ya Nan LAN ; Da Wei LI ; Ji Peng YU ; Yuan PANG ; Xue Qiu QIN ; Hao LIANG ; Kao Kao ZHU ; Li YE ; Bing Yu LIANG
Biomedical and Environmental Sciences 2023;36(9):800-813
OBJECTIVE:
This study aimed to determine the HIV-1 subtype distribution and HIV drug resistance (HIVDR) in patients with ART failure from 2014 to 2020 in Hainan, China.
METHODS:
A 7-year cross-sectional study was conducted among HIV/AIDS patients with ART failure in Hainan. We used online subtyping tools and the maximum likelihood phylogenetic tree to confirm the HIV subtypes with pol sequences. Drug resistance mutations (DRMs) were analyzed using the Stanford University HIV Drug Resistance Database.
RESULTS:
A total of 307 HIV-infected patients with ART failure were included, and 241 available pol sequences were obtained. Among 241 patients, CRF01_AE accounted for 68.88%, followed by CRF07_BC (17.00%) and eight other subtypes (14.12%). The overall prevalence of HIVDR was 61.41%, and the HIVDR against non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide reverse transcriptase inhibitors (NRTIs), and protease inhibitors (PIs) were 59.75%, 45.64%, and 2.49%, respectively. Unemployed patients, hypoimmunity or opportunistic infections in individuals, and samples from 2017 to 2020 increased the odd ratios of HIVDR. Also, HIVDR was less likely to affect female patients. The common DRMs to NNRTIs were K103N (21.99%) and Y181C (20.33%), and M184V (28.21%) and K65R (19.09%) were the main DRMs against NRTIs.
CONCLUSION
The present study highlights the HIV-1 subtype diversity in Hainan and the importance of HIVDR surveillance over a long period.
Humans
;
Reverse Transcriptase Inhibitors/therapeutic use*
;
HIV-1/genetics*
;
Cross-Sectional Studies
;
Phylogeny
;
Anti-HIV Agents/therapeutic use*
;
Drug Resistance, Viral/genetics*
;
HIV Infections/epidemiology*
;
Mutation
;
China/epidemiology*
;
Prevalence
;
Genotype
3.Effect of Acute Myeloid Leukemia Cells on the Proliferation and Apoptosis of Bone Marrow-Derived Mesenchymal Stromal Cells.
Ze-Hui CHEN ; Ya-Xin ZHENG ; Jun-Qi SI ; Tian YUAN ; Zhi-Rong ZHANG ; Chen TIAN
Journal of Experimental Hematology 2022;30(2):430-434
OBJECTIVE:
To investigate the effect of acute myeloid leukemia cells in leukemia-microenvironment on proliferation and apoptosis of bone marrow-derived mesenchymal stromal cells (BM-MSC).
METHODS:
Acute myeloid leukemia (AML) murine models overexpressing MLL-AF9 were established. The number of BM-MSC of wild type (WT) and AML-derived mice were analyzed by flow cytometry. Morphology and growth differences between WT and AML-derived BM-MSC were analyzed by inverted fluorescence microscope. Proliferation and apoptosis of BM-MSC between these two groups were detected by Brdu and Annexin V/PI.
RESULTS:
Compared with WT-derived BM-MSC, the number and proliferation rate of AML-derived BM-MSC significantly increased (P<0.01, P<0.001), while apoptosis rate decreased (P<0.05). When cultured in vitro, BM-MSC grew faster under conditional medium.
CONCLUSION
AML cells can promote proliferation and inhibit apoptosis of BM-MSC.
Animals
;
Apoptosis
;
Bone Marrow
;
Bone Marrow Cells
;
Cell Proliferation
;
Humans
;
Leukemia, Myeloid, Acute
;
Mesenchymal Stem Cells
;
Mice
;
Tumor Microenvironment
4.Bone Marrow Osteoblasts Promotes the Proliferation Leukemia Stem Cell by Up-regulating Interleukin-1.
Zhi-Jie CAO ; Yi-Shuang LI ; Hui-Jun WANG ; Zhen-Ya XUE ; Shu-Ying CHEN ; Ke-Jing TANG ; Min WANG ; Qing RAO
Journal of Experimental Hematology 2022;30(5):1348-1353
OBJECTIVE:
To explore the extrinsic regulation mechanism of bone marrow microenvironment in leukemia cells, and investigate the promoting effect of osteoblast niche on the proliferation and self-renewal of leukemia stem cell by up-regulating the expression of interleukin-1 (IL-1) in leukemia cell.
METHODS:
The gene expression profiles on leukemia cells derived from AE9a mouse bone marrow endosteum and central bone marrow were determined by RNA sequencing and gene set enrichment analysis (GSEA). Quantitative real-time PCR (qRT-PCR) was used to detect the expression of IL-1 in AE9a mouse leukemia cells co-cultured with or without osteoblasts in vitro. In addition, qRT-PCR was also used to determine the expression of IL-1 in bone marrow mononuclear cell (BMMNC) from 43 patients with acute myeloid leukemia (AML). For leukemia cells co-cultured with osteoblasts or treated with IL-1β, colony forming ability of AE9a leukemia cells was determined by colony formation assay.
RESULTS:
In AE9a leukemia mouse, RNA-seq data and GSEA showed that the enrichment of the upregulated genes in leukemia cells located in endosteum fell into inflammatory response gene set, among them, IL-1α and IL-1β were significantly higher expressed in AE9a leukemia cells that located osteoblast niche (IL-1α: P<0.001, IL-1β:P<0.001). After AE9a leukemia cells were co-cultured with osteoblasts in vitro, the expression of IL-1α and IL-1β in leukemia cells were increased by 2.5 and 3.5 times respectively. In colony formation assay, the number of colonies was increased significantly after leukemia cells were co-cultured with osteoblasts (P<0.001). In addition, when AE9a leukemia cells were treated with IL-1β, the number of colonies was also increased significantly (P<0.01). In AML patients, BMMNC with high percentage of CD34 positive cells exhibited higher level of IL-1 expression.
CONCLUSION
Osteoblast niche can promote leukemia cell proliferation and self-renewal through up-regulating the expression of IL-1 in leukemia cells. In AML patients, the expression level of IL-1 was correlated to the percentage of CD34 positive cells in BMMNC.
Animals
;
Antigens, CD34/metabolism*
;
Bone Marrow/metabolism*
;
Cell Proliferation
;
Leukemia, Myeloid, Acute/metabolism*
;
Mice
;
Osteoblasts/metabolism*
;
Stem Cells
;
Tumor Microenvironment
5.Animal Model Establishment and Its Mechanism of Cytarabine-Iduced Myelosuppression.
Ya-Ling LI ; Wei CHU ; Jun-Jie LI ; Juan-Juan DONG ; Gao-Qin LI ; Xiao-Jie JIN ; Juan YAO ; Yong-Qi LIU
Journal of Experimental Hematology 2022;30(5):1376-1383
OBJECTIVE:
To establish an optimized model of bone marrow suppression induced by cytarabine (Ara-C) in C57BL/6 mice and preliminarily explore the mechanism of myelosuppression based on the cycle and apoptosis of BMNC.
METHODS:
C57BL/6 mice were intraperitoneally injected with Ara-C 50, 100 and 200 mg/kg for 7 days, respectively. The survival rate and body weight of C57BL/6 mice were monitored. The number of peripheral blood cells and bone marrow nucleated cells (BMNC) was detected, and the morphology of bone marrow, thymus and spleen were measured on the 7th, 14th and 21st day of the experiment. The cycle and apoptosis of BMNC were also detected by flow cytometry.
RESULTS:
Ara-C 200 mg/kg caused 46.7% mortality in mice, and other doses had no significant effect on mortality. All doses of Ara-C induced bone marrow suppression in mice, as shown by a decrease in the number of peripheral blood cells (WBC, Neu, RBC, PLT) and BMNC (P<0.05), decrease in bone marrow hyperplasia, accompanied by immunosuppression and compensatory hematopoiesis of the spleen, and the above manifestations and duration were dose-dependent. Among them, the myelosuppression caused by Ara-C 50 mg/kg recovered quickly, and caused by Ara-C 200 mg/kg was too severe. The result of flow cytometry showed that Ara-C could cause S and G2/m arrest and increased apoptosis in BMNC.
CONCLUSION
Ara-C can induce myelosuppression in mice with a dose-dependent severity and duration, and the model of myelosuppression with Ara-C 100 mg/kg is more optimized. The mechanism is related to the inhibition of BMNC proliferation and the promotion of apoptosis.
Animals
;
Bone Marrow Cells
;
Bone Marrow Diseases
;
Cytarabine/adverse effects*
;
Disease Models, Animal
;
Mice
;
Mice, Inbred C57BL
6.Mechanism Underlying the Inhibitory Effect of MiR-532-3p on the Cells Proliferation of Diffuse Large B-Cell Lymphoma.
Yan ZHANG ; Qian YAO ; Jian-Jun JIN ; Ya-Ming XI
Journal of Experimental Hematology 2022;30(5):1423-1427
OBJECTIVE:
To investigate the effects and underlying mechanism of miR-532-3p and resibufogenin (RES) by regulating Wnt/β-catenin signaling on diffuse Large B-cell lymphoma (DLBCL) cells proliferation.
METHODS:
DLBCL tissues and adjacent normal tissues were collected from patients had been diagnosed with DLBCL at the First Hospital of Lanzhou University from October 2019 to October 2021. Four groups including mimics-NC, miR-532-3p mimics, RES control and RES treatment in SU-DHL-4 cells were designed. The expression level of miR-532-3p was detected by RT-qPCR. The protein content of β-catenin was detected by Western blot. MTT assay was used to detect the proliferation activity of SU-DHL-4 cells.
RESULTS:
miR-532-3p expression was significantly decreased in DLBCL tissues compared with adjacent normal tissues (P<0.001). The miR-532-3p content in lymphoma cells was significantly lower than that in normal lymphocytes (P<0.001). After overexpression of miR-532-3p, the viability of SU-DHL 4 cells was significantly decreased (P<0.001), with a reduced expression of β-catenin (P<0.05). RES treatment inhibited the proliferation of SU-DHL-4 cells and decreased β-catenin expression in SU-DHL-4 cells compared with the control group.
CONCLUSION
Overexpression of miR-532-3p reduced Wnt/β-catenin signaling and inhibited the proliferation of lymphoma cells. Moreover, RES treatment inhibited lymphoma cells growth partially through Wnt/β-catenin signaling suppression.
Cell Line, Tumor
;
Cell Proliferation
;
Humans
;
Lymphoma, Large B-Cell, Diffuse/genetics*
;
MicroRNAs/metabolism*
;
Wnt Signaling Pathway
;
beta Catenin
7.Optimization of Mouse Model of Aplastic Anemia Induced by Pan T Lymphocytes Combined with Irradiation.
Yu-Jie BIAN ; Wei-Wang LI ; Meng-Ke LI ; Bi-Chen WANG ; De-Yang SHI ; Jun SHI ; Wei-Ping YUAN ; Ya-Jing CHU
Journal of Experimental Hematology 2021;29(2):557-566
METHODS:
To establish the acquired aplastic anemia mouse model through the X-ray irradiation in combination with lymphocytes injection. AA Group: the purified Pan T lymphocytes from the spleen of C57BL/6J mice were enriched and injected to the mice through tail vein(5×10
RESULTS:
Compared with 4, 5 Gy irradiated mice in AA groups, the survival time of 3 Gy irradiated AA groups was significantly prolonged. 3, 4 and 5 Gy X-ray irradiation combined with Pan T lymphocyte injection could successfully induced severe reduction of red blood cells, blood neutrophils, and platelets, severe reduction of bone marrow nucleated cells, severe bone marrow hematopoietic failure, and the significant expansion of T lymphocytes ratio in the bone marrow. CD4
CONCLUSION
3, 4 and 5 Gy X-ray irradiation combined with 5×10
Anemia, Aplastic
;
Animals
;
Bone Marrow
;
Bone Marrow Cells
;
CD8-Positive T-Lymphocytes
;
Humans
;
Mice
;
Mice, Inbred C57BL
8.Association between
Ming-Xuan CAI ; Bing WEI ; Shi-E LIAO ; Jin-Yue FU ; Ya-Jun LIU ; Ling-Xue LI
Chinese Journal of Contemporary Pediatrics 2021;23(11):1132-1140
OBJECTIVES:
To study the association of β2-drenergic receptor (
METHODS:
A total of 143 children with asthma who attended the hospital from October 2016 to October 2020 were enrolled as the asthma group, among whom 61 children had mild symptoms (mild group) and 82 children had moderate-to-severe symptoms (moderate-to-severe group). A total of 137 healthy children were enrolled as the control group. Peripheral venous blood samples were collected from the two groups. The SNaPshot SNP technique was used to analyze the SNP and haplotypes of the
RESULTS:
Polymorphisms were observed in the
CONCLUSIONS
SNP/haplotype of the
Asthma/genetics*
;
Case-Control Studies
;
Child
;
Genetic Predisposition to Disease
;
Genotype
;
Haplotypes
;
Humans
;
Polymorphism, Single Nucleotide
;
Receptors, Adrenergic, beta-2/genetics*
;
Regulatory Sequences, Nucleic Acid
9.Clinical Significance of Platelet Closure Time in Patients with Multiple Myeloma.
Ya-Nan TANG ; Hu-Jun LI ; Ya-Qi WU ; Ting XU ; Meng-Jun GE ; Kai-Lin XU ; Zheng-Yu LI
Journal of Experimental Hematology 2020;28(4):1240-1244
OBJECTIVE:
To explore the clinical significance of platelet closure time (PCT) in patients with multiple myeloma (MM).
METHODS:
Peripheral blood samples of 50 newly diagnosed MM patients treated in our hospital from July 2018 to November 2019 and 34 healthy persons underuent physical at the same time were collected. PCT induced by collagen/epinephrine (CEPI) and collagen/adenosinediphosphate (CADP) in peripheral blood were detected by PFA-200,and the clinical data included age, sex, leukocyte count, hemoglobin level, platelet count and level of serum creatinine, cystatin c, blood calcium, β-microglobulin (β-MG), bone marrow plasma cells, light chain protein, as well as the MM types, ISS stage of patients were collected.
RESULTS:
The level of PCT in MM patients was significantly higher than that in healthy persons; the level of PCT were significantly increased with the increasing of ISS stage in newly diagnosed MM patients; After chemotherapy with bortezomib/dexamethasone (BD), the level of PCT in 15 patients who were responded to the treatment was significantly lower than those before treatment.
CONCLUSION
The platelet closure time is abnormal in MM patients, moreover, relates to the progress of the disease. It has an important clinical significance for the evaluation of diagnostic stage and therapeutic efficacy evaluation of MM patients.
Blood Platelets
;
Bone Marrow
;
Bortezomib
;
Humans
;
Multiple Myeloma
;
Platelet Count
10.Expression of Versican and Its Related Molecules in Patient with Multiple Myeloma and Its Clinical Significance.
Ya-Qi WU ; Lu-Yao LUO ; Ya-Nan TANG ; Hu-Jun LI ; Yan-Jie LI ; Ying WANG ; Yao YAO ; De-Peng LI ; Kai-Lin XU ; Zhen-Yu LI
Journal of Experimental Hematology 2020;28(4):1228-1233
OBJECTIVE:
To investigate the expression and clinical significant of VCAN and its related molecules in patients with MM.
METHODS:
Ficoll density gradient centrifugation method was used to speared the bone marrow mononuclear cell in 25 cases of MM before and after treatment, the relative mRNA expression of VCAN and their related molecules (FAK, FN, MK, and HAS) in bone marrow was detected by real-time quantitative PCR, and their protein expression was determined by Western bolt.
RESULTS:
The expression of VCAN, FK and FN in the effective group after treatment was significantly lower than that before treatment (P<0.05), however, the expression of MK and HAS showed no statistically significantly different before and after treatment (P<0.05). The expression of VCAN of patients in non remission group was significantly higher than that in control group (P<0.05). The expression of FAK and FN of patients in no remission group was significant increased as compared with the patients in newly diagnosed group (P<0.05). The relative expression of VCAN mRNA in the patients at 3rd stage was significantly higher than those at the 1st stage (P<0.05) and control group but showed no significant difference to the patients at 2nd stage (P<0.05). The expression of VCAN and its related proteins (FAK, MK, FN) showed positively correlation in bone marrow mononuclear cells of MM patients (P<0.05). The correlation between VCAN and HAS was not statistically significant (r=0.259,P>0.05). Survival analysis showed that the relative expression of VCAN mRNA was associated with OS (P=0.049) and PFS (P=0.041) in MM patients.
CONCLUSION
VCAN and its related molecules are highly expressed in MM patients; VCAN may act as potential biomarker in the development of multiple myeloma.
Bone Marrow
;
Humans
;
Multiple Myeloma
;
RNA, Messenger
;
Versicans

Result Analysis
Print
Save
E-mail